SEHK:2269Life Sciences
WuXi Biologics Chengdu Milestone Raises Questions On Capacity Use And Returns
WuXi Biologics (Cayman) reached structural completion of its new microbial commercial manufacturing facility in Chengdu.
The company has taken delivery of key equipment at the site, moving closer to GMP-ready large-scale production of microbial-derived biologics targeted by the end of 2026.
The Chengdu facility includes China's first dual-chamber lyophilization production line and high automation to support complex biologics manufacturing and efficiency.
ESG-focused green building practices...